Our Pipeline - Pioneering Mitochondrial DNA Technology
In addition to the Prostate Core Mitomic Test™, Mitomics is using our proprietary Mitomic Technology™ to develop an advanced pipeline of product solutions for disease detection and prognosis. All of these novel tests will offer high accuracy, and most will be non-invasive. Mitomic Tests are currently in development for the early detection or characterization of:
- Prostate cancer
- Breast cancer
- Uterine cancer
- Cervical cancer
- Colorectal cancer
- Melanoma, skin cancer and other dermatological conditions
Prostate Positive Mitomic Test is a tissue-based test to determine prostate cancer tumor behavior, specifically whether the tumor is potentially aggressive or slow-growing, and whether the tumor has the propensity to become aggressive. Prostate Positive Mitomic Test may enable urologists to more appropriately monitor and treat prostate cancer patients.
Prostate Mitomic Test is a urine-based screening test for the accurate prediction of prostate cancer following an elevated PSA level. This prostate cancer-specific assay is used to stratify which patients need or do not need to undergo a prostate gland biopsy. Due to well-known limitations with PSA testing alone, Prostate Mitomic Test will enable urologists to make more accurate biopsy decisions.
Breast Mitomic Test is a rapid, accurate, early detection tool for breast cancer screening using Nipple Aspirate Fluid (NAF). A more comfortable method for patients than mammography, the Breast Mitomic Test can be used as an early detection and annual screening tool for women aged 18 years and older. Meanwhile, mammography is not considered to be effective in women under the age of 50 years as this imaging modality cannot penetrate the dense breast tissue of younger women. Additionally, the Breast Mitomic Test detects at the cellular level, while mammography is unable to find tumors of less than 1 cm in diameter.
Endometrial Mitomic Test is a menstrual blood-based, non-invasive, screening test to detect endometriosis in high-risk patients and women of reproductive age. The current standard for the diagnosis of endometriosis is through laparoscopic surgery and an ectopic endometrial tissue sample. Endometrial Mitomic Test may provide physicians with a non-invasive, non-surgical, highly accurate alternative to detect endometriosis.